ReviewJournal of Cancer2020
The Effect of the Tumor Microenvironment and Tumor-Derived Metabolites on Dendritic Cell Function.
Review in Journal of Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Advances in oncolytic virus delivery strategies and challenges in clinical translation.Materials today. Bio · 2026Review
- Review
- Review
- Overcoming immune resistance in ovarian cancer: checkpoint inhibitors, tumor microenvironment, and translational advances.Frontiers in oncology · 2026Review
- Special Issue "Dendritic Cell and Cancer Therapy 2.0".International journal of molecular sciences · 2025Article
- Adoptively transferred macrophages for cancer immunotherapy.Journal for immunotherapy of cancer · 2025Article
- 4-Octyl Itaconate Modulates Dendritic Cells Function and Tumor Immunity via NRF2 Activation.Journal of inflammation research · 2025Article
- The role of tumor microenvironment and self-organization in cancer progression: Key insights for therapeutic development.BioImpacts : BI · 2025Review
- A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives.Journal of immunotherapy and precision oncology · 2024Review
- Dysfunction of dendritic cells in tumor microenvironment and immunotherapy.Cancer communications (London, England) · 2024Review
- Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined Therapies.International journal of molecular sciences · 2024Review
- A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule.Pharmaceutics · 2024Article
- Exploring the potential use of Chinese herbs in regulating the inflammatory microenvironment of tumours based on the concept of 'state-target identification and treatment': a scooping review.Chinese medicine · 2023Review
- Virus-like Particles for TEM Regulation and Antitumor Therapy.Journal of functional biomaterials · 2022Review
- Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.Cancer immunology, immunotherapy : CII · 2022Article
- Immune cell metabolism and metabolic reprogramming.Molecular biology reports · 2022Review
- Friends with Benefits: Chemokines, Glioblastoma-Associated Microglia/Macrophages, and Tumor Microenvironment.International journal of molecular sciences · 2022Review
- TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma.International journal of molecular sciences · 2021Article
- The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?Cancer immunology, immunotherapy : CII · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) have a critical effect on the outcome of adaptive immune responses against growing tumors. Recent studies on the metabolism on DCs provide new insights on the functioning of these critical controllers of innate and adaptive immunity. DCs within the tumor microenvironment (TME) often exist in an inactive state, which is thought to limit the adaptive immune response elicited by the growing tumor. Tumor-derived factors in the TME are known to suppress DC activation and result in functional alterations in DC phenotype. We are now beginning to appreciate that many of these factors can also induce changes in immune cell metabolism. In this review, we discuss the functional alternation of DC phenotype by tumor metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.